Skip to main content

Physician Search

 

Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives.

https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine.

https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/

Displaying 81 - 90 of 287

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Myelodysplastic Syndrome

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with
azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).
Myelodysplastic Syndrome
I/II
Kishtagari, Ashwin
NCT04417517
VICCHEMP2084

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Miscellaneous

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and
tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in
combination with ruxolitinib in participants with MF who are transfusion-dependent or
presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and
expansion.
Miscellaneous
I/II
Mohan, Sanjay
NCT04455841
VICCHEMP2051

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase I

This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the safety
profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint
inhibitor (CPI) pembrolizumab (Keytruda).
Phase I
I
Davis, Elizabeth
NCT04198766
VICCPHI2135

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Multiple Cancer Types

Clinical study to investigate the efficacy and safety of savolitinib in combination with
osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated,
MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed
on treatment with Osimertinib.
Lung, Non Small Cell
III
Iams, Wade
NCT05261399
VICCTHO2219

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Gurin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Bladder

The purpose of this study is to evaluate the overall complete response (CR) rate in
participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone
(Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without
concomitant high-grade Ta or T1 papillary disease.
Bladder
II
Luckenbaugh, Amy
NCT04640623
VICCURO2106

Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant

Multiple Cancer Types

This phase I/II trial studies the side effects and best dose of vorinostat in preventing graft versus host disease in children, adolescents, and young adults who are undergoing unrelated donor blood and bone marrow transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells, called graft-versus-host disease. During this process, chemicals (called cytokines) are released that may damage certain body tissues, including the gut, liver and skin. Vorinostat may be an effective treatment for graft-versus-host disease caused by a bone marrow transplant.
Hematologic, Pediatric Leukemia, Pediatric Lymphoma
I/II
Kitko, Carrie
NCT03842696
VICCPED2133

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic
(PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
Multiple Myeloma
I
Mohan, Sanjay
NCT03309111
VICCHEMP17111

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and
tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV
as monotherapy and in combination with pembrolizumab in patients with recurrent, locally
advanced, or metastatic HPV16+ solid tumors. The study includes patients with head and neck,
cervical, anal, vulvar, or penile cancer.
Not Available
I/II
Iams, Wade
NCT05357898
VICCPHI2264

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Multiple Cancer Types

In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer
(TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676
and pembrolizumab following radiotherapy. The main aims of this study are to check if people
are improving after treatment with TAK-676, getting side effects from these combined
treatments, and how much TAK-676 people with these cancers can receive without getting
unacceptable side effects from it.

Participants will receive radiotherapy, then at least 40 hours later will receive
pembrolizumab followed by TAK-676 slowly through a vein (infusion). Participants will receive
an infusion of pembrolizumab at the same dose every 3 weeks. Different small groups of
participants will receive lower to higher doses of TAK-676 on specific days of a 21-day
cycle. This study will be happening at sites in North America.
Head/Neck, Lung, Non Small Cell, Phase I
I
Iams, Wade
NCT04879849
VICCHNP20120

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in
combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Melanoma
II
Johnson, Douglas
NCT04577807
VICCMEL20109